Table 1.
Baseline demographic characteristics of the included patients.
| Characteristics | All (N = 122) | BRCA1/2 mutation | |||
|---|---|---|---|---|---|
| Positive (N = 42) | Negative (N = 61) | Unknown (N = 19) | |||
| Age (years), median (IQR) | 57 (49–68) | 56 (48–66) | 62 (54–69) | 53 (42–62) | |
| < 60 years, N (%) | 65 (53.3) | 27 (64.3) | 26 (42.6) | 12 (63.2) | |
| ≥ 60 years, N (%) | 57 (46.7) | 15 (35.7) | 35 (57.4) | 7 (36.8) | |
| FIGO stage, N (%) | |||||
| 2 | 2 (1.6) | 0 (0) | 0 (0) | 2 (10.5) | |
| ≥ 3 | 98 (80.3) | 39 (92.9) | 50 (82.0) | 9 (47.4) | |
| Unknown | 22 (18.0) | 3 (7.1) | 11 (18.0) | 8 (42.1) | |
| ECOG PS, N (%) | |||||
| 0 | 91 (74.6) | 31 (73.8) | 45 (73.8) | 15 (78.9) | |
| 1–2 | 31 (25.4) | 11 (26.2) | 16 (26.2) | 4 (21.1) | |
| Histology type, N (%) | |||||
| Serous | 115 (94.3) | 40 (95.2) | 57 (93.4) | 18 (94.7) | |
| Endometrioid | 6 (4.9) | 2 (4.8) | 3 (4.9) | 1 (5.3) | |
| Others | 1 (0.8) | 0 (0) | 1 (1.6) | 0 (0) | |
| Previous platinum regimens, N (%) | |||||
| ≤ 2 | 118 (96.7) | 41 (97.6) | 58 (95.1) | 19 (100) | |
| > 2 | 4 (3.3) | 1 (2.4) | 3 (4.9) | 0 (0) | |
| PFI, N (%) | |||||
| 6–12 months | 62 (50.8) | 22 (52.4) | 30 (49.2) | 10 (52.6) | |
| ≥ 12 months | 60 (49.2) | 20 (47.6) | 31 (50.8) | 9 (47.4) | |
| CA125 level before olaparib treatment, N (%) | |||||
| ≤ 35 U/mL | (93.2) | 34 (81.0) | 45 (73.8) | 14 (73.7) | |
| > 35 U/mL | 29 (23.8) | 8 (19.0) | 16 (26.2) | 5 (26.3) | |
| Response to the last platinum dose according to RECIST | |||||
| Complete response, N (%) | 20 (16.4) | 7 (16.7) | 11 (18.0) | 2 (10.5) | |
| Partial response, N (%) | 102 (83.6) | 35 (83.3) | 50 (82.0) | 17 (89.5) | |
| NLR, median (IQR) | 1.9 (1.5–2.5) | 1.7 (1.3–2.2) | 1.9 (1.5–2.7) | 1.9 (1.5–2.1) | |
| PLR, median (IQR) | 172 (139–214) | 170 (141–209) | 176 (142–217) | 178 (105–285) | |
BRCA breast cancer susceptibility gene, IQR interquartile range, FIGO International Federation of Gynecology and Obstetrics, ECOG PS Eastern Cooperative Oncology Group performance status, PFI platinum-free interval, CA-125 cancer antigen 125, RECIST Response Evaluation Criteria in Solid Tumors, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.